Drug Approval | May 25, 2026
EU regulator backs Allergan Aesthetics’ Boey in key step toward approval
The decision marks a key step in the centralized EU review process
The decision marks a key step in the centralized EU review process
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The move targets long-standing bottlenecks in MSC science, including cell-to-cell variability, immunocompatibility concerns, and inefficient manufacturing workflows
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
By cutting pain crises & boosting haemoglobin
The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
